EAST - AFNET 4 has been completed!

After almost a decade of successful team work we will finally have the results and will be able to answer the question whether an early and comprehensive rhythm control therapy has the potential to prevent adverse outcomes in patients with atrial fibrillation.

Together we have maneuvered the trial to completion. A pan-European trial like EAST – AFNET 4 invol­ves a lot of people and requires their cooperation for many years.  Thank you very much to all health professionals for their constant commitment! And also a big thank you to all participating patients who were willing to support this scientific challenge. Due to their endurance we will achieve a high quality of data.

Patient Recruitment ended on December 31, 2016. 2,789 patients have been enrolled. In toal, 135 ever recruiting study sites in 11 countries particpated in the EAST – AFNET 4 study.

EAST – AFNET 4 reached the end of observation period on 6 March 2020 ahead of schedule and finally the end of study (EOS) on 31 May 2020.

The results were presented during one of the main hot line sessions of the 2020 Digital ESC Congress, today, 29 August 2020, 17:00 CEST. The accompanying publication has also been published.

Press release

Publication

The EAST - AFNET 4 trial was partially funded by the German Centre for Cardiovascular Research (DZHK) and other partners.

EAST – AFNET 4 is registered at ClinicalTrials.gov, ISRTCN, and EU Clinical Trials Register

ClinicalTrials.gov: NCT01288352
http://clinicaltrials.gov/ct2/show/NCT01288352?term=NCT01288352&rank=1

ISRCTN04708680
http://www.controlled-trials.com/ISRCTN04708680

EU Clinical Trials Register
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2010-021258-20